HealthInvest Partners AB Buys Shares of 96,345 Autolus Therapeutics plc (NASDAQ:AUTL)

HealthInvest Partners AB purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 96,345 shares of the company’s stock, valued at approximately $620,000.

Several other hedge funds also recently modified their holdings of AUTL. Renaissance Technologies LLC acquired a new position in Autolus Therapeutics during the 2nd quarter valued at $36,000. Two Sigma Advisers LP acquired a new stake in Autolus Therapeutics during the first quarter worth about $25,000. Jane Street Group LLC bought a new position in Autolus Therapeutics during the second quarter valued at about $42,000. CI Private Wealth LLC acquired a new position in Autolus Therapeutics in the 4th quarter valued at approximately $28,000. Finally, Sei Investments Co. acquired a new position in Autolus Therapeutics in the 4th quarter valued at approximately $29,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Price Performance

Shares of AUTL traded down $0.04 during trading hours on Tuesday, hitting $4.86. The stock had a trading volume of 612,011 shares, compared to its average volume of 1,523,960. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -4.17 and a beta of 1.90. The company’s fifty day moving average is $6.01 and its two-hundred day moving average is $5.06. Autolus Therapeutics plc has a 52 week low of $1.61 and a 52 week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.18). Equities analysts predict that Autolus Therapeutics plc will post -0.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AUTL shares. Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Friday. Truist Financial raised their price objective on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.16.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.